In this study we demonstrated that the absence of HTATIP2 expression in A549 human NSCLC cells resulted in accelerated tumor growth despite stalled tumor neovascularization and reduced tumor oxygenation, and lowered tumor sensitivity to sorafenib treatment. This evidence concerns the gene HTATIP2 and non-small cell lung carcinoma.